You may qualify for a study at the University of Alabama at Birmingham exploring the effects of sacubitril/valsartan on your ...

The PARADIGM-HF and PARAGON-HF trials demonstrated consistent benefits of sacubitril/valsartan relative to RAS inhibitors in ...

The Food and Drug Administration (FDA) has issued a Class II recall for over 7,000 bottles of duloxetine, a popular ...

The Food and Drug Administration announced a Class II recall for more than 7,000 bottles of an antidepressant due to a ...

This article explores the top five worst foods for heart health and provides healthy alternatives to promote better ...

GLP-1 medications, such as Ozempic, may interact with other drugs, causing very low blood sugar levels or disrupting the ...

The following is a summary of “Impact of Race on Sacubitril/Valsartan use of HF,” published in the October 2024 issue of Cardiology by Lu et al. There is limited understanding of how self-reported ...

In another such trial (VALUE), researchers randomized 15,245 hypertensive patients (minimum age, 50; mean BP, 155/87 mm Hg) in 31 countries to receive the angiotensin-receptor blocker valsartan or ...

Objectives: To assess the efficacy and tolerability of valsartan and valsartan plus hydrochlorothiazide (HCTZ), given alone or as part of a combination regimen with other antihypertensive agents ...

In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart ...

Sacubitril/valsartan significantly reduces NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF) over 3 years, with no significant changes in sST2 and galectin-3.

The 4,822-patient study missed statistical significance for a composite primary endpoint of reducing cardiovascular death and total heart failure hospitalisations by 13% compared with valsartan ...